MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback